TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer.
Jingde ChenYanan HaiQingqing HuChen ChenXiaohua JiangYong GaoPublished in: Pharmaceutical research (2022)
Our findings suggested that TGF-β signaling may take a significant part in anlotinib resistance in GC. The suppression of TGF-β signaling may be a possible and promising approach for the GC oncotherapy when combined with anlotinib.